Related Experiment Videos
Coronary artery thrombolysis: comparison of approved agents
1Hahnemann University School of Medicine, Philadelphia, Pennsylvania.
Insights
Alteplase is the most effective thrombolytic agent for coronary artery thrombosis, showing higher patency rates than anistreplase or streptokinase. Early administration, within one hour, significantly improves recanalization outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Emergency Medicine
Background:
- Coronary artery thrombosis necessitates prompt treatment with thrombolytic agents.
- Several agents, including alteplase, anistreplase, and streptokinase, are approved for this purpose.
- Clinical trials are essential to compare their efficacy and safety.
Purpose of the Study:
- To compare the efficacy of alteplase, anistreplase, and streptokinase in restoring coronary artery patency.
- To evaluate the impact of early administration and adjunctive therapies on thrombolytic treatment outcomes.
Main Methods:
- Clinical experimental trials conducted in Europe and the United States.
- Comparative analysis of recanalization and patency rates for the three thrombolytic agents.
- Assessment of agent-specific characteristics like allergenicity and feasibility of repeat administration.
Main Results:
- Alteplase demonstrated higher efficacy (71% patency) compared to anistreplase (60%) and streptokinase (58%).
- Streptokinase and anistreplase are allergenic, limiting repeat administration, a disadvantage compared to alteplase.
- Optimal recanalization rates (≥90%) are achievable with administration within the first hour post-thrombosis.
Conclusions:
- Alteplase offers a slight efficacy advantage and better suitability for repeat administration in thrombolytic therapy.
- Adjunctive therapies like aspirin and heparin, alongside precise dosing, enhance efficacy but increase bleeding risk.
- Expanding administration settings to pre-hospital environments could enable earlier treatment and improve patient outcomes.
Abstract:
Three agents approved for the lysis of thrombi in coronary arteries--alteplase, anistreplase and streptokinase--have undergone critical clinical experimental trials in Europe and the United States. Global comparison of their efficacy shows that alteplase is slightly more effective (71 percent) in restoring patency than anistreplase (60 percent) and streptokinase (58 percent). Streptokinase and anistreplase are allergenic, and repeat administration is not feasible in the short-term, a distinct advantage for alteplase. More accurate dosing of thrombolytic agents and skillful use of aspirin and heparin improve the efficacy of thrombolytic therapy but can also increase the risk of bleeding. A recanalization rate of 90 percent or more could be achieved if the thrombolytic agent is administered within the first hour after thrombosis. Administration this soon after the development of thrombosis may be possible if the agent is given outside the hospital by practicing physicians or, perhaps, paramedics.